Invited Review
Sex differences in the response to opioids for pain relief: A systematic review and meta-analysis

https://doi.org/10.1016/j.phrs.2019.104447Get rights and content

Abstract

There are conflicting results about sex differences in the response to opioids for pain control and the role of potential influencing factors of these differences has not been investigated. We meta-analyzed differences and similarities between men and women in opioid response for pain control and investigated the potential influence of baseline pain intensity, age, body weight, and other factors in these findings.
PubMed, Scopus, and Cochrane CENTRAL were searched through January 15, 2019, for clinical studies in which opioids were administered for pain control. We included clinical studies in which (a) opioids were used to treat acute or chronic pain, (b) the response to opioids was broken down for men and women, and (c) the response to opioids was reported as (i) difference between baseline and final Visual Analog Scale of Pain Intensity (VASPI) score 30 min after opioid administration (Delta-VASPI at 30′), or daily dose of opioids (ii) self-administered by patients (patient-controlled analgesia PCA), or (iii) administered by physicians. Risk of bias was evaluated using ROBINS-I and the overall quality of evidence for primary outcomes was evaluated using the GRADE system.
Globally, we included 40 comparisons (6794 patients). Regarding acute pain, we found moderate quality of evidence that women and men do not differ in their response to opioids 30 min after their administration [Delta-VASPI at 30′: mean difference, MD = 0.42 (−0.07; 0.91)]. We also found moderate quality of evidence that women self-administer lower daily amounts of opioids [daily PCA: standardized mean difference, SMD = −0.30 (−0.41; −0.18)]. Regarding chronic pain, we found low quality of evidence that women receive lower daily doses for non-cancer pain [MD = −36.42 (−57.86; –14.99)]. By contrast, we found very low quality of evidence that women and men do not differ in the daily dose of opioids for cancer pain [MD = −16.09 (−40.13; 7.94)]. Age, comorbid mental disorders, type of administration, type of opioids, type of patients, and body weight significantly modified these results.
In conclusion, the results of the present meta-analysis suggest that men and women may differ in the response to opioids for pain relief, but these differences as well as similarities are significantly influenced by factors like age and comorbid mental disorders. However, the role of these factors is not usually evaluated in the prescription of opioids for pain control. There is an urgent need to conduct clinical trials on the use of opioid medications for pain, in which information about all possible influencing factors are provided and broken down for men and women.

Introduction

Opioids are the most frequently prescribed drugs for severe, acute [1] or chronic cancer, and non-cancer pain [2]. Their widespread use for chronic pain has contributed to the recent opioid epidemic [3,4].
Differences in both sex (related to biological effects) and gender (related to psycho-socio-cultural effects) have been described in pain sensitivity, tolerance to painful stimuli, prevalence of some chronic pain conditions [5,6] and in the safety, tolerability, efficacy and abuse liability of opioids [7,10]. For instance, certain chronic pain conditions, such as fibromyalgia, migraine, and osteoarthritis, are more frequent in women than men, and women seem to perceive certain painful stimuli as more intense than men [11]. Women also seem to be at higher risk of developing severe postoperative pain than men [12]. The neurobiological basis of these differences is not completely understood, but they seem to be the result of complex interactions between sex and gender effects, together with previous pain experiences [12].
While women receive opioid prescriptions twice as frequently as men [10], it is unclear whether women need less opioid to achieve pain relief. Some studies suggest that women require lower doses of opioids, or higher doses, and other studies did not find sex differences in the dose of opioids to achieve pain relief [13]. Several factors may have influenced these conflicting findings, including differences in the perception of pain at baseline, the type of opioid administered, the dose and the route of administration [e.g., fixed doses or patient-controlled analgesia (PCA)], age-related hormonal status, and comorbid psychiatric disorders [6,9]. For example, men and women metabolize opioids differently [14]. The effects of opioids primarily metabolized by the enzyme CYP3A4 (e.g., fentanyl) may be lower in women than in men, given that the hepatic expression of CYP3A4 is higher in women than men. On the other hand, the effects of opioids like codeine, primarily metabolized by the enzyme CYP2D6, whose hepatic expression is higher in men than women, may be lower in men than in women. Opioid metabolism may be further influenced by exogenous and endogenous sex hormones that are substrates of CYP3A4 and CYP2D6 [15]. Since opioids are lipophilic and men and women differ in body composition (women have more body fat than men) and body weight (BW, on average, women weigh less than men), administration of fixed doses of opioids, not adjusted according to BW, may result in higher blood concentrations in women [8,14,16]. Additionally, the menstrual cycle influences pain thresholds [14], pharmacokinetics [8], analgesic effect [6,17,18], and susceptibility to the side effects of opioids [18]. Furthermore, addictive and mental disorders are common among patients using opioid analgesia [19], and there are large sex/gender differences in their prevalence [17].
In summary, these factors may account for the variability on the interaction between sex/gender and exposure to opioids. To our knowledge, the role of these potential influencing factors has not been systematically investigated in sex variability to the response to opioids. In this meta-analysis, we aimed to investigate the role of potential influencing factors like baseline pain intensity, BW, comorbid mental disorders, type of administration (e.g., fixed doses, dose adjusted according to BW, or PCA), mean age, phase of the menstrual cycle, typology of participants, and use of alcohol, tobacco, or cannabis in sex differences in the response to opioids for pain control. We hypothesized that these factors may be able to influence sex similarities and/or differences in the response to opioids for pain control. To achieve this aim, we first conducted a systematic review and a meta-analysis to evaluate the presence of similarities and differences between men and women in the response to opioids for pain control. Then, we investigated whether the results of the meta-analysis were modified by the potential influencing factors mentioned above.

Access through your organization

Check access to the full text by signing in through your organization.

Access through your organization

Section snippets

Search strategy

We conducted a systematic review and meta-analysis in line with the PRISMA guidelines, following an a priori–defined protocol (see Supplementary material). We searched PubMed (Medline), Scopus, and Cochrane Central Register of Controlled Trials (CENTRAL), with no date limitation, using the following search strategy: “opioids AND pain AND sex differences”, opioid OR morphine OR nalbuphine OR pentazocine OR fentanyl OR hydrocodone OR hydromorphone OR tramadol OR buprenorphine) response and

Results

Our search identified 3640 articles, 1002 of which were duplicates. Sixty-seven additional articles were identified through references for a total of 2705 articles (Fig. 1).
A total of 2678 articles were excluded (see Supplementary material). Among these articles, three were not retrieved, despite a request to the authors. Twenty-seven articles were identified that met all inclusion criteria and none of the exclusion criteria.

Discussion

This meta-analysis evaluated sex differences in response to opioids for pain relief and the role of potential influencing factors. We included 4134 participants (1743 men; 2391 women) with acute pain, and 2660 (1080 men; 1580 women) with chronic pain.
In terms of acute pain, we found moderate quality of evidence for the lack of sex differences in the response to opioids reported as Delta-VASPI at 30′. Conversely, when the response was reported as daily PCA, we found moderate quality of evidence

Conclusions

Despite many years of extensive use of opioids to treat chronic and acute pain, knowledge about potential sex differences and similarities in the effective and safe dose needed to relieve pain remains scarce. Furthermore, the paucity of available data, and the lack of information about potential influencing factors does not allow any firm conclusions on their role and importance for physicians when they have to prescribe an opioid medication for pain (for example, when they have to establish

Funding sources

This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. It was partially supported by a grant from the University of Cagliari to RA (FIR 2018). CP is supported by a Fondazione Umberto Veronesi fellowship. LL is supported by the National Institutes of Health (NIH) intramural funding ZIA-AA000218, Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, jointly supported by the Division of Intramural Clinical and

Declaration of Competing Interest

None.

Acknowledgements

The authors are grateful to Drs. Antonio Preti and Pier Paolo Pani for their assistance in the evaluation of the quality of evidence of the meta-analysis.

References (61)

  • G.H. Guyatt et al.

    GRADE guidelines: 5. Rating the quality of evidence--publication bias

    J. Clin. Epidemiol.

    (2011)
  • P.E. Bijur et al.

    Intravenous bolus of ultra-low-dose naloxone added to morphine does not enhance analgesia in emergency department patients

    J. Pain

    (2006)
  • A.K. Chang et al.

    Safety and efficacy of hydromorphone as an analgesic alternative to morphine in acute pain: a randomized clinical trial

    Ann. Emerg. Med.

    (2006)
  • R.W. Gear et al.

    Gender difference in analgesic response to the kappa-opioid pentazocine

    Neurosci. Lett.

    (1996)
  • R.W. Gear et al.

    The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain

    Pain

    (1999)
  • R.W. Gear et al.

    Dose ratio is important in maximizing naloxone enhancement of nalbuphine analgesia in humans

    Neurosci. Lett.

    (2003)
  • N.C. Gordon et al.

    Enhancement of morphine analgesia by the GABAB agonist baclofen

    Neuroscience

    (1995)
  • P.E. Macintyre et al.

    Age is the best predictor of postoperative morphine requirements

    Pain.

    (1996)
  • K.A. Donovan et al.

    Sex differences in the adequacy of pain management among patients referred to a multidisciplinary cancer pain clinic

    J. Pain Symptom Manage.

    (2008)
  • J.M. Edrington et al.

    No evidence for sex differences in the severity and treatment of cancer pain

    J. Pain Symptom Manage.

    (2004)
  • D. Dowell et al.

    CDC Guideline for prescribing opioids for chronic pain-United States

    JAMA

    (2016)
  • A. Schuchat et al.

    New Data on opioid use and prescribing in the United States

    JAMA

    (2017)
  • N.D. Volkow et al.

    Prevention and treatment of opioid misuse and addiction: a review

    JAMA Psychiatry

    (2019)
  • J.S. Mogil

    Sex differences in pain and pain inhibition: multiple explanations of a controversial phenomenon

    Nat. Rev. Neurosci.

    (2012)
  • R. Agabio et al.

    Sex differences in substance use disorders: focus on side effects

    Addict. Biol.

    (2016)
  • F. Franconi et al.

    Sex impact on biomarkers, pharmacokinetics and pharmacodynamics

    Curr. Med. Chem.

    (2017)
  • M. Serdarevic et al.

    Sex differences in prescription opioid use

    Curr. Opin. Psychiatry

    (2017)
  • F. Franconi et al.

    Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women

    Br. J. Pharmacol.

    (2014)
  • K. Klein et al.

    Pharmacogenomics of Cytochrome P450 3A4: recent progress toward the "missing heritability" problem

    Front. Genet.

    (2013)
  • I. Campesi et al.

    Sex and gender aspects in anesthetics and pain medication

    Handb. Exp. Pharmacol.

    (2012)
  • Cited by (65)

    • The anatomy of pain and suffering in the brain and its clinical implications

      2021, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      Therefore, morphine may be less effective in females (Shansky and Murphy, 2021), and generate more neuroinflammation induced sensitization, important for chronification. A meta-analysis suggests that men and women may indeed differ in the response to opioids for pain relief, but these differences as well as similarities are significantly influenced by factors like age and comorbid mental disorders (Pisanu et al., 2019), as evident from the above paragraphs showing a hormonal influence and different sex-dependent prevalence in anxiety and depression. Interestingly, not all treatments for chronic pain show a clear sex-dependent effect.

    View all citing articles on Scopus
    1
    Equally contributed.
    View full text